BRIEF: Cloudbreak launches $78 million Hong Kong IPO
Ophthalmic biotech company Cloudbreak Pharma Inc. (2592.HK) launched its Hong Kong IPO on Tuesday, aiming to sell 60.58 million shares at HK$10.10 apiece to raise about HK$610 million ($78 million). Share…
BRIEF: Green Economy invests $1.48 million in Bayed Health Group IPO
Building maintenance services company Green Economy Development Ltd. (1315.HK) said on Wednesday it will invest HK$11.6 million ($1.48 million) in shares of Bayzed Health Group Inc. (2609.HK) during the biotech…
BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) launched its Hong Kong IPO on Thursday, aiming to sell 225 million shares at a price range of HK$41.45 to HK$44.05 per share,…
BRIEF: Duality Biotherapies surges in Hong Kong trading debut
Shares of biotech firm Duality Biotherapeutics Inc. (9606.HK) opened up 91% at HK$181 on Tuesday and continued to climb in their Hong Kong trading debut, closing up 127% at HK$214.80…
Neautus looks outward to boost its traditional medicine story
The maker of traditional Chinese medicines has applied for a Hong Kong IPO after abandoning two listing attempts on China’s domestic A-share market Key Takeaways: Neautus has applied to list…
BRIEF: WuXi XDC’s revenue, profit jump in 2024
WuXi XDC Cayman Inc. (2268.HK), a provider of contract services for drug companies, said on Wednesday its revenue and profit rose sharply last year on strong demand for services related…
BRIEF: Wai Yuen Tong profit rises six-fold on non-operational gains
Drug and healthcare products maker Wai Yuen Tong Medicine Holdings Ltd. (0897.HK) announced on Wednesday its revenue fell 5.8% year-on-year to HK$347 million ($45 million) in the six months to…